Prosecution Insights
Last updated: November 20, 2026
Application No. 17/961,299

RADIOLABELED COMPOUNDS TARGETING THE PROSTATE-SPECIFIC MEMBRANE ANTIGEN

Non-Final OA §112§DOUBLEPATENT
Filed
Oct 06, 2022
Priority
Jun 21, 2019 — provisional 62/865,088 +3 more
Examiner
PERREIRA, MELISSA JEAN
Art Unit
1618
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
The University of British Columbia
OA Round
1 (Non-Final)
52%
Grant Probability
Moderate
1-2
OA Rounds
0m
Est. Remaining
78%
With Interview

Examiner Intelligence

Grants 52% of resolved cases
52%
Career Allowance Rate
436 granted / 837 resolved
-7.9% vs TC avg
Strong +26% interview lift
Without
With
+25.7%
Interview Lift
resolved cases with interview
Typical timeline
3y 9m
Avg Prosecution
36 currently pending
Career history
885
Total Applications
across all art units

Statute-Specific Performance

§101
2.1%
-37.9% vs TC avg
§103
56.0%
+16.0% vs TC avg
§102
12.7%
-27.3% vs TC avg
§112
16.6%
-23.4% vs TC avg
Black line = Tech Center average estimate • Based on career data from 837 resolved cases

Office Action

§112 §DOUBLEPATENT
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Election/Restrictions Applicant's election with traverse of group I in the reply filed on 8/24/26 is acknowledged. The traversal is on the ground(s) that searching and examining the claims 15-20 drawn to using the very same searched formula II for treating a PSMA-expressing condition or disease and imaging does not require any different searches for substituents, linker moieties and radiometal chelators. This is not found persuasive because the compounds of group I comprise so many possible variations and unlimited number of possible combinations of chemical moieties and further searching for the methods of treating and/or imaging of the infinite number of compounds of group I will cause a search burden to the Office. The requirement is still deemed proper and is therefore made FINAL. Claim 15-20 are withdrawn from further consideration pursuant to 37 CFR 1.142(b), as being drawn to a nonelected groups, there being no allowable generic or linking claim. Applicant timely traversed the restriction (election) requirement in the reply filed on 8/24/26. Claim Rejections - 35 USC § 112 The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claims 1-9 and 11-14 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. The instant claims are confusing and unclear as the compounds of Formula (II) comprise a Markush structure containing so many possible variations, such as the combination of R2 ,R7,R11,R12, and Rx moieties wherein R11 may be present or may not be present and the ring systems of R10 may be optionally modified to include various substituents or additional endocyclic ring nitrogen atoms. The many possible variations of the substitutions and different possible chelating moieties of different sizes and functions yields compounds of different sizes and that may form various conformations. The compounds of the instant claims comprise numerous different structures so that the scope of the claims cannot be determined. While breadth alone is not indefinite, the instant claims have an almost unlimited number of possible combinations of chemical moieties that it is not possible to determine the metes and bounds of the claims. The dependent claims fall therewith. Claims 11-9 and 11-14 are rejected on the judicially-created basis that it contains an improper Markush grouping of alternatives. See In re Harnisch, 631 F.2d 716, 721-22 (CCPA 1980) and Ex parte Hozumi, 3 USPQ2d 1059, 1060 (Bd. Pat. App. & Int. 1984). The improper Markush grouping includes species of the claimed invention that do not share both a substantial structural feature and a common use that flows from the substantial structural feature. A Markush claim contains an “improper Markush grouping” if: (1) the species of the Markush group do not share a single structural similarity,” or (2) the species do not share a common use. Members of a Markush group share a "single structural similarity” when they belong to the same recognized physical or chemical class or to the same recognized physical or chemical class or to the same art-recognized class. Members of a Markush group share a common use when they are disclosed in the specification or known in the art to be functionally equivalent (see Federal Register, Vol. 76, No. 27, Wednesday, February 9, 2011, p. 7166, left and middle columns, bridging paragraph). The claims are directed to compounds of Formula (II) comprise a Markush structure containing so many possible variations, such as the combination of R2 ,R7,R11,R12, and Rx moieties wherein R11 may be present or may not be present and the ring systems of R10 may be optionally modified to include various substituents or additional endocyclic ring nitrogen atoms. The many possible variations substitutions and different possible chelating moieties of different sizes and functions yields compounds of different sizes and that may form various conformations. The compounds of the instant claims comprise numerous different structures so that the scope of the claim cannot be determined, instant claims have an almost unlimited number of possible combinations of chemical moieties and there is nothing of record to show a common chemical core that is specifically tied to a function in the almost unlimited breadth of the claimed compounds. Applicant attention is directed to the third paragraph of MPEP 803.02 which discloses: “Since the decisions in In re Weber, 580 F.2d 455, 198 USPQ 328 (CCPA 1978) and In re Haas, 580 F.2d 461, 198 USPQ 334 (CCPA 1978), it is improper for the Office to refuse to examine that which Applicants regard as their invention, unless the subject matter in a claim lacks unity of invention. In re Harnisch, 631 F.2d 716, 206 USPQ 300 (CCPA 1980); and Ex parte Hozumi, 3 USPQ2d 1059 (Bd. Pat. App. & Int. 1984). Broadly, unity of invention exists where compounds included within a Markush group (1) share a common utility, and (2) share a substantial structural feature essential to that utility.” In the instant case, if it is asserted that the claims share a common utility, it is noted the only shared structures are urea and PNG media_image1.png 82 234 media_image1.png Greyscale that does not allow the genus to have an art recognized classification. Hence, the Markush grouping is improper. In response to this rejection, Applicant should either amend the claim(s) to recite only individual species or grouping of species that share a substantial structural feature as well as a common use that flows from the substantial structural feature, or present a sufficient showing that the species recited in the alternative of the claims(s) in fact share a substantial structural feature as well as a common use that flows from the substantial structural feature. This is a rejection on the merits and may be appealed to the Board of Patent Appeals and Interferences in accordance with 35 U.S.C. §134 and 37 CFR 41.31(a)(1) (emphasis provided). The dependent claims fall therewith. Double Patenting The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the “right to exclude” granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., In re Berg, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); In re Goodman, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); In re Longi, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); In re Van Ornum, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); In re Vogel, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); In re Thorington, 418 F.2d 528, 163 USPQ 644 (CCPA 1969). A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on nonstatutory double patenting provided the reference application or patent either is shown to be commonly owned with the examined application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement. See MPEP § 717.02 for applications subject to examination under the first inventor to file provisions of the AIA as explained in MPEP § 2159. See MPEP § 2146 et seq. for applications not subject to examination under the first inventor to file provisions of the AIA . A terminal disclaimer must be signed in compliance with 37 CFR 1.321(b). The filing of a terminal disclaimer by itself is not a complete reply to a nonstatutory double patenting (NSDP) rejection. A complete reply requires that the terminal disclaimer be accompanied by a reply requesting reconsideration of the prior Office action. Even where the NSDP rejection is provisional the reply must be complete. See MPEP § 804, subsection I.B.1. For a reply to a non-final Office action, see 37 CFR 1.111(a). For a reply to final Office action, see 37 CFR 1.113(c). A request for reconsideration while not provided for in 37 CFR 1.113(c) may be filed after final for consideration. See MPEP §§ 706.07(e) and 714.13. The USPTO Internet website contains terminal disclaimer forms which may be used. Please visit www.uspto.gov/patent/patents-forms. The actual filing date of the application in which the form is filed determines what form (e.g., PTO/SB/25, PTO/SB/26, PTO/AIA /25, or PTO/AIA /26) should be used. A web-based eTerminal Disclaimer may be filled out completely online using web-screens. An eTerminal Disclaimer that meets all requirements is auto-processed and approved immediately upon submission. For more information about eTerminal Disclaimers, refer to www.uspto.gov/patents/apply/applying-online/eterminal-disclaimer. Claims 1-9,11,13 and 14 are provisionally rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1-5,7-27,35-38,40-43 and 45-50 of copending Application No. 18/996,309 (reference application). Although the claims at issue are not identical, they are not patentably distinct from each other because the compound of Formula I PNG media_image2.png 112 260 media_image2.png Greyscale of copending Application No. 18/996,309 encompasses the compound of Formula II PNG media_image3.png 110 268 media_image3.png Greyscale of the instant claims as they comprise the same corresponding substituents for R1a-R1c, R0, R3, PNG media_image4.png 24 132 media_image4.png Greyscale is PNG media_image5.png 158 152 media_image5.png Greyscale , R7 PNG media_image6.png 30 102 media_image6.png Greyscale , especially R2 is -CH2CHF-, -CHFCH2-, -CH2OCH2-, -CH2SCH2-. The method of imaging prostate specific membrane antigen (PSMA)-expressing tissues of copending Application No. 18/996,309 comprises the compounds of Formula I that encompass the compounds of Formula II of the instant claims that are capable of imaging prostate specific membrane antigen (PSMA)-expressing tissues. This is a provisional nonstatutory double patenting rejection because the patentably indistinct claims have not in fact been patented. Claims 1-9,11 and 13 are provisionally rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1-3,19-21,23,25,27,28,31-34,44,45,47,48,50-52,55 and 57-59 of copending Application No. 18/842,681 (reference application). Although the claims at issue are not identical, they are not patentably distinct from each other because the compound of Formula I PNG media_image7.png 208 602 media_image7.png Greyscale encompasses the compound of Formula II PNG media_image3.png 110 268 media_image3.png Greyscale of the instant claims as they comprise the same corresponding substituents for R2, R3,L1-L7,R4, R5a-5b,R6, PNG media_image5.png 158 152 media_image5.png Greyscale , especially R1 is -CH2CHF-, -OCH2-, -SCH2-. The compounds of copending Application No. 18/842,681 further comprise compounds, such as PNG media_image8.png 228 458 media_image8.png Greyscale that encompass the PNG media_image9.png 244 440 media_image9.png Greyscale of the instant claims. The method of treating prostate specific membrane antigen (PSMA)-expressing tissues of copending Application No. 18/842,681 comprises the compounds of Formula I that encompass the compounds of Formula II of the instant claims that are capable of treating prostate specific membrane antigen (PSMA)-expressing tissues. This is a provisional nonstatutory double patenting rejection because the patentably indistinct claims have not in fact been patented. Claims 1-9,11,13 and 14 are provisionally rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1,3,4,7-18,41-44,46 and 47 of copending Application No. 18/267,987 (reference application). Although the claims at issue are not identical, they are not patentably distinct from each other because the compound of Formula B PNG media_image10.png 124 378 media_image10.png Greyscale of copending Application No. 18/267,987 encompasses the compound of Formula II PNG media_image3.png 110 268 media_image3.png Greyscale of the instant claims as they comprise the same corresponding substituents for R1a-R1c, R0a-R0c, PNG media_image4.png 24 132 media_image4.png Greyscale is PNG media_image5.png 158 152 media_image5.png Greyscale , R7, especially R2 is -CH2CHF-, -CHFCH2-, -CH2OCH2-, -CH2SCH2-. The compounds of copending Application No. 18/267,987 further comprise compounds, such as PNG media_image11.png 238 322 media_image11.png Greyscale that encompass the PNG media_image12.png 244 426 media_image12.png Greyscale of the instant claims. The method of imaging and/or treating prostate specific membrane antigen (PSMA)-expressing tissues of copending Application No. 18/267,987 comprises the compounds of Formula I that encompass the compounds of Formula II of the instant claims that are capable of imaging and/or treating prostate specific membrane antigen (PSMA)-expressing tissues This is a provisional nonstatutory double patenting rejection because the patentably indistinct claims have not in fact been patented. Relevant Prior Art Besenova et al.(WO 2018/215627) discloses the compounds PNG media_image13.png 230 434 media_image13.png Greyscale (p12) wherein R4 comprises F, etc. (p14) but does not disclose the F at the position corresponding to the compounds of Formula II of the instant claims. Conclusion No claims are allowed at this time. Any inquiry concerning this communication or earlier communications from the examiner should be directed to MELISSA JEAN PERREIRA whose telephone number is (571)272-1354. The examiner can normally be reached M9-3, T9-3, W9-3, Th9-2, F9-2. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Michael Hartley can be reached at 571-272-0616. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /MELISSA J PERREIRA/Examiner, Art Unit 1618
Read full office action

Prosecution Timeline

Oct 06, 2022
Application Filed
Oct 26, 2026
Non-Final Rejection mailed — §112, §DOUBLEPATENT (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12797072
COLLAGEN MATRIX AND N-HYDROXYLSUCCINIMIDE FUNCTIONALIZED POLYETHYLENE GLYCOL STAPLE LINE REINFORCEMENT
4y 8m to grant Granted Nov 17, 2026
Patent 12758660
IMAGING AND RADIOTHERAPEUTICS AGENTS TARGETING FIBROBLAST-ACTIVATION PROTEIN-ALPHA (FAP-ALPHA)
6y 5m to grant Granted Oct 13, 2026
Patent 12746297
RADIOFREQUENCY AMPLIFICATION BY STIMULATED EMISSION OF RADIATION VIA PARAHYDROGEN INDUCED POLARIZATION
5y 6m to grant Granted Sep 29, 2026
Patent 12734258
RADIOLIGANDS FOR PRETARGETED PET IMAGING AND METHODS OF THEIR THERAPEUTIC USE
5y 0m to grant Granted Sep 15, 2026
Patent 12714754
DELIVERY OF CYCLIC COMPOUND BY USING CARRIER
4y 12m to grant Granted Aug 25, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
52%
Grant Probability
78%
With Interview (+25.7%)
3y 9m (~0m remaining)
Median Time to Grant
Low
PTA Risk
Based on 837 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month